BRCA1 and breast cancer: This systematic review confirms that RRM and RRSO are cost-effective compared to surveillance/no action in women at a high risk of BC/OC (mainly for BRCA1/2 PV carriers), with RRSO also being cost-effective in women at a 4–5% intermediate lifetime OC risk, and that changes in clinical guidelines need to reflect this.